Insilico Medicine advances generative AI-designed COVID-19 drug.
Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19
February 23, 2023 09:00 ET | InSilico Medicine
New York, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s...
Launch of Insilico Medicine's AI and Quantum Computing R&D Center in Abu Dhabi
Insilico Medicine Opens Largest AI-Powered Biotechnology Research Center in the Middle East
February 01, 2023 09:27 ET | InSilico Medicine
Abu Dhabi, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage artificial intelligence (AI)-driven drug discovery company, is announcing today the opening of the...
Insilico Medicine at 41st Annual J.P. Morgan Healthcare Conference
Insilico Medicine to Present at 41st Annual J.P. Morgan Healthcare Meeting
November 29, 2022 09:00 ET | InSilico Medicine
New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine will present at the  41st Annual J.P. Morgan Healthcare Meeting happening Jan. 9-12, 2023 at the Westin St. Francis Hotel in San...
Advancing AI Drug Discovery
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
November 08, 2022 09:00 ET | InSilico Medicine
Abu Dhabi, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research...
Advancing AI Drug Discovery
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
November 08, 2022 09:00 ET | InSilico Medicine
New York, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research...